InMed Pharmaceuticals Announces the Appointment of Dr. Sazzad Hossain, PhD, MSc, as a Member of the Scientific Advisory Board and his Retirement as Chief Scientific Officer


VANCOUVER, Jan. 11, 2019 /PRNewswire/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that Dr. Sazzad Hossain, PhD, MSc, will assume a position as member of the Scientific Advisory Board (“SAB”) and, contemporaneously, announced his retirement as Chief Scientific Officer (“CSO”).  Dr. Eric C. Hsu, PhD, Vice President, Pre-Clinical Research Development, will continue to lead the scientific RD programs of the Company.

InMed Pharmaceuticals Inc.<p> more at  <a href=